MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/epi4.12349

Медицинская библиотека · Epilepsia open · 2019

Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy.

Silvennoinen Katri, de Lange Nikola, Zagaglia Sara, Balestrini Simona, Androsova Ganna, Wassenaar Merel, Auce Pauls, Avbersek Andreja, Becker Felicitas, Berghuis Bianca, Campbell Ellen, Coppola Antonietta, Francis Ben, Wolking Stefan, Cavalleri Gianpiero L, Craig John, Delanty Norman, Johnson Michael R, Koeleman Bobby P C, Kunz Wolfram S, Lerche Holger, Marson Anthony G, O'Brien Terence J, Sander Josemir W, Sills Graeme J, Striano Pasquale, Zara Federico, van der Palen Job, Krause Roland, Depondt Chantal, Sisodiya Sanjay M, EpiPGX Consortium

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To study the effectiveness and tolerability of antiepileptic drugs (AEDs) commonly used in juvenile myoclonic epilepsy (JME).

METHODS

People with JME were identified from a large database of individuals with epilepsy, which includes detailed retrospective information on AED use. We assessed secular changes in AED use and calculated rates of response (12-month seizure freedom) and adverse drug reactions (ADRs) for the five most common AEDs. Retention was modeled with a Cox proportional hazards model. We compared valproate use between males and females.

RESULTS

We included 305 people with 688 AED trials of valproate, lamotrigine, levetiracetam, carbamazepine, and topiramate. Valproate and carbamazepine were most often prescribed as the first AED. The response rate to valproate was highest among the five AEDs (42.7%), and significantly higher than response rates for lamotrigine, carbamazepine, and topiramate; the difference to the response rate to levetiracetam (37.1%) was not significant. The rates of ADRs were highest for topiramate (45.5%) and valproate (37.5%). Commonest ADRs included weight change, lethargy, and tremor. In the Cox proportional hazards model, later start year (1.10 [1.08-1.13], P < 0.001) and female sex (1.41 [1.07-1.85], P = 0.02) were associated with shorter trial duration. Valproate was associated with the longest treatment duration; trials with carbamazepine and topiramate were significantly shorter (HR [CI]: 3.29 [2.15-5.02], P < 0.001 and 1.93 [1.31-2.86], P < 0.001). The relative frequency of valproate trials shows a decreasing trend since 2003 while there is an increasing trend for levetiracetam. Fewer females than males received valproate (76.2% vs 92.6%, P = 0.001).

SIGNIFICANCE: In people with JME, valproate is an effective AED; levetiracetam emerged as an alternative. Valproate is now contraindicated in women of childbearing potential without special precautions. With appropriate selection and safeguards in place, valproate should remain available as a therapy, including as an alternative for women of childbearing potential whose seizures are resistant to other treatments.

Для цитирования: Silvennoinen Katri, de Lange Nikola, Zagaglia Sara, Balestrini Simona, Androsova Ganna, Wassenaar Merel, Auce Pauls, Avbersek Andreja, Becker Felicitas, Berghuis Bianca, Campbell Ellen, Coppola Antonietta, Francis Ben, Wolking Stefan, Cavalleri Gianpiero L, Craig John, Delanty Norman, Johnson Michael R, Koeleman Bobby P C, Kunz Wolfram S, Lerche Holger, Marson Anthony G, O'Brien Terence J, Sander Josemir W, Sills Graeme J, Striano Pasquale, Zara Federico, van der Palen Job, Krause Roland, Depondt Chantal, Sisodiya Sanjay M, EpiPGX Consortium. Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy.. Epilepsia open. 2019. DOI: 10.1002/epi4.12349.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.